Dr Lal PathLabs

February 02, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results for the quarter and nine months ended December 31, 2016

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results for the Quarter and nine months ended December 31, 2016.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary & Legal Head

Encl: As above

For Immediate Release **February 2, 2017**

Dr. Lal PathLabs Limited records growth of 10% in Q3 FY2016-17

New Delhi, India, Feb 2, 2017 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended Dec 31, 2016

Consolidated Performance Highlights: Q3FY2016-17 vs. Q3FY2015-16

- Operating Revenue increased by 10% Y-o-Y to Rs. 2075 million vs Rs 1886 million in the previous year. Underlying volume growth is 5.2%. 9 months YTD DQ FY'17 revenue grew at 16.7% to Rs 6925 million with underlying volume growth at 11.4%
- Normalised EBITDA increased by 10.1% Y-o-Y to Rs.470 million from Rs 427 million in the same quarter last year, after adjusting for ESOP provisions/reversals in Previous year financials. YTD 9months EBITDA at Rs 1872 million grew at 23.1%.
- EBITDA Margin was 22.6% for Q3 FY17 vs 22.6% in Q3 FY16. For 9 months YTD, EBITDA margins are at 27% vs 25.6% in Previous year. Normalised PBT improved by 17.4% in Q3 and by 28.6% YTD 9 months.
- Profit after Tax in Q3 shows a decline to Rs. 310 million from Rs 611 million in previous year on account of the impact of ESOP reversals in Q3 last year. 9 months YTD PAT increased from Rs 986 million to Rs 1240 million. The PAT numbers are not strictly comparable for Q3 as previous year had an ESOP reversal of Rs 440 million in Q3.
- The Board at its meeting held on Feb 2, 2017 has recommended an interim dividend of Rs 1.30 per share of Rs 10 each for FY17.

Financial Overview (Consolidated) in Rs mn

Rs Mn

Particulars	DQ FY 17	DQ FY 16	Gr %	9MFY17	9MFY16	Gr %	12MFY16
Total Revenue	**2,074.7**	**1,885.7**	***10.0%***	**6,924.8**	**5,936.1**	***16.7%***	**7,913.2**
Total Expenditure	1,605.0	1,185.1		5,052.9	4,380.2		5,816.0
EBITDA	469.7	700.6		1,871.9	1,555.9	***20.3%***	2,097.2
ESOP charges reversal	-	*(273.8)*		-	*(34.7)*		*(34.7)*
Normalised EBITDA excl ESOP	**469.7**	**426.8**	***10.1%***	**1,871.9**	**1,521.2**	***23.1%***	**2,062.5**
Normalised Margins	*22.6%*	*22.6%*		*27.0%*	*25.6%*		*26.1%*
ESOP - Exceptional charges reversed	**-**	(166.3)		**-**	**-**		**-**
Other income incl interest	*67.1*	*44.2*		*189.9*	*136.0*		*197.7*
PBT excl ESOP reversals	**465.1**	**396.2**	***17.4%***	**1,858.3**	**1,444.7**	***28.6%***	**2,007.2**
Margins	*22.4%*	*21.0%*		*26.8%*	*24.3%*		*25.4%*
PAT	**310.0**	**611.1**	***-49.3%***	**1,240.3**	**985.8**	***25.8%***	**1,332.3**
Margins	*14.9%*	*32.4%*		*17.9%*	*16.6%*		*16.8%*
EPS (Diluted)	**3.70**	**7.31**	**-49.4%**	**14.79**	**11.83**	**25.0%**	**15.98**

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, 171 other clinical laboratories, 1,559 patient service centers and nearly 5,000 pickup points as of March 31, 2016. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Dilip Bidani
Dr. Lal PathLabs Limited
+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR
+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.